What You Should Know:
– Genetic Leap, a pioneering AI-native techbio company, has entered into a strategic research collaboration with Eli Lilly and Company.
– The partnership aims to develop innovative genetic medicine therapeutics using Genetic Leap’s cutting-edge RNA-targeted AI platform.
Leveraging AI to Revolutionize RNA Drug Discovery
RNA genetic medicine holds immense promise for addressing a wide range of diseases. By targeting RNA, scientists can potentially develop therapies for conditions such as cancer, genetic disorders, and infectious diseases.
RNA plays a crucial role in regulating gene expression and protein production. By targeting RNA, scientists can potentially develop new therapies for diseases that have been difficult to treat with traditional drugs. However, drugging RNA has presented significant challenges due to its complex structure and interactions.
Genetic Leap’s AI platform is revolutionizing the approach to RNA drug discovery. By utilizing advanced AI algorithms, the platform can identify novel RNA targets and design potential drug candidates with high specificity and efficacy.
Eli Lilly Collaboration
The collaboration between Genetic Leap and Eli Lilly builds upon a successful pilot project and will focus on developing genetic medicine therapeutics for high-priority therapeutic areas. Genetic Leap will receive up to $495M in funding from Eli Lilly, including upfront payments and milestone payments, as well as tiered royalties.
“We are thrilled to collaborate with Lilly and deeply share their strong commitment to developing RNA medicines,” said Dr. Bertrand Adanve, CEO and founder of Genetic Leap. “Our primary goal in building the Genetic Leap AI platform is to accelerate the development of life-saving medicines for patients, and this collaboration with Lilly’s talented and savvy R&D team takes us significantly closer to that goal.”